NRX Pharmaceuticals Inc
NASDAQ:NRXP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
LM Pay SA
XBER:Y00
|
PL |
|
A
|
AstraZeneca PLC
LSE:0A4J
|
UK |
|
I
|
Il Dong Pharmaceutical Co Ltd
KRX:249420
|
KR |
|
S
|
Shimano Inc
OTC:SMNNY
|
JP |
|
3
|
361 Degrees International Ltd
SWB:36L
|
CN |
NRX Pharmaceuticals Inc
Research & Development
NRX Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NRX Pharmaceuticals Inc
NASDAQ:NRXP
|
Research & Development
-$3.8m
|
CAGR 3-Years
39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
NRX Pharmaceuticals Inc
Glance View
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. NRX-101 is a fixed-dose combination of D-cycloserine and lurasidone for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB). Its ZYESAMI (aviptadil) is an investigational drug for COVID-19-related respiratory failure. The firm has completed a Phase IIb/III clinical study in patients with acute respiratory failure in COVID-19.
See Also
What is NRX Pharmaceuticals Inc's Research & Development?
Research & Development
-3.8m
USD
Based on the financial report for Dec 31, 2025, NRX Pharmaceuticals Inc's Research & Development amounts to -3.8m USD.
What is NRX Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 3Y
39%
Over the last year, the Research & Development growth was 39%. The average annual Research & Development growth rates for NRX Pharmaceuticals Inc have been 39% over the past three years .
